Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bioxytran Inc (OP:BIXT)

0.0407 -0.0012 (-2.86%)
Streaming Delayed Price Updated: 3:51 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bioxytran Inc

News headline image
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
Via ACCESS Newswire
News headline image
Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus
Via ACCESS Newswire
News headline image
Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus
From Bioxytran, Inc
Via ACN Newswire
News headline image
Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate’s Ability to Block H5N1 Bird Flu Virus
Via Press Release Distribution Service
Topics Economy
News headline image
Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline
From Bioxytran
Via ACN Newswire
News headline image
Bioxytran's Medical Breakthrough in Fighting All Viruses
Via ACCESSWIRE
News headline image
Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement
Via ACCESS Newswire
News headline image
Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement
From Bioxytran, Inc
Via ACN Newswire
News headline image
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
Via Get News
News headline image
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
From Bioxytran, Inc
Via ACN Newswire
News headline image
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
Via Press Release Distribution Service
News headline image
Bioxytran CEO David Platt, Ph.D. to Present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference
Via Get News
Topics Regulatory Compliance
News headline image
Bioxytran CEO David Platt, Ph.D. to Present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference
Via Press Release Distribution Service
Topics Regulatory Compliance
News headline image
Bioxytran CEO David Platt, Ph.D. to Present at Noble Capital Markets' Emerging Growth Virtual Equity Conference
Via ACCESS Newswire
News headline image
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
Via ACCESS Newswire
News headline image
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
From Bioxytran, Inc
Via ACN Newswire
News headline image
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
Via Get News
News headline image
Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline
Via Get News
News headline image
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
Via Press Release Distribution Service
News headline image
Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline
Via Press Release Distribution Service
News headline image
Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements
Via Get News
News headline image
Bioxytran Establishes Indian Subsidiary in Preparation of Commercialization
From BIOXYTRAN, INC.
Via GlobeNewswire
News headline image
Bioxytran Interview at the Emerging Growth Conference
From BIOXYTRAN, INC.
Via GlobeNewswire
News headline image
Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients
From BIOXYTRAN, INC.
Via GlobeNewswire
News headline image
Bioxytran, Inc. Announces the Reinitiation of Coverage of Its Stock by Avise Analytics
From BIOXYTRAN, INC.
Via GlobeNewswire
While COVID-19 Drags On, Biotechs Introduce New Treatments & Vaccines to Combat Subvariants
EQNX::TICKER_START (OTCQB:BIXT),(NASDAQ:NVAX),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:INO),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Bioxytran Releases Positive Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in medRxiv Pre-print
Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001) Complete elimination of viral load in 88% of patients at day 3 vs 0% in placebo (p=.001) Treated population... 
Via FinancialNewsMedia
News headline image
Bioxytran Scientific Advisor Releases New Book on Brain Metabolism
From BIOXYTRAN, INC.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS